22nd Century Group Inc(XXII) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 6:04 PM ET (Korea 9/16 07:04)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -644.21 | Insider Own | 22.77% | Shs Outstand | 0.7M | Perf Week | -21.62% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.6M | Perf Month | -58.5% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 9.31% | Short Float | 7.85% | Perf Quarter | -70.77% |
| Income | -0.03B | P/S | 0.09 | EPS this Y | - | Inst Trans | 29.71% | Short Ratio | 1.57 | Perf Half Y | -97.58% |
| Sales | 0.01B | P/B | 0.05 | EPS next 5Y | - | ROA | -52.86% | Short Interest | 0.04M | Perf YTD | -99.22% |
| Book/sh | 37.07 | P/C | 0.21 | EPS past 3/5Y | 98.99% 87.27% | ROE | -105.73% | 52W High | -99.72% ($646.50) | Perf Year | -99.65% |
| Cash/sh | 8.49 | P/FCF | - | Sales past 3/5Y | -24.27% -8.95% | ROIC | -20.03% | 52W Low | -0.28% ($1.80) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.95% | Gross Margin | -22.15% | Volatility(W/M) | 8.71% 11.78% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -0.21 | Sales Y/Y TTM | -27.44% | Oper. Margin | -84% | ATR (14) | 0.32 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.9 | EPS Q/Q | 97.45% | Profit Margin | -237.82% | RSI (14) | 23 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.61 | Sales Q/Q | -29.86% | SMA20 | -36.98% ($2.84) | Beta | 0.68 | Target Price | $2700 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/13 | SMA50 | -51.28% ($3.67) | Rel Volume | 0.79 | Prev Close | $1.85 |
| Employees | 32 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | -97.89% ($84.83) | Avg Volume(3M) | 0.03M | Price | $1.79 |
| IPO | 2011/1/26 | Option/Short | No/Yes | Trades | 348 | Volume | 21,657 | Change | -2.97% |
Company
XXII is a Consumer Defensive sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
An innovative life sciences company dedicated to reducing the harm caused by smoking. It has pioneered a new product category with FDA-approved low-nicotine cigarettes designed to reduce smokers' health damage and lower nicotine addiction.
Over the past 1 year, on the lower side
100% below its 1-year high.
XXII has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -100.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 9.3%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $1M.
XXII $1M PER -
PM $303B PER 27.9
BTI $122B PER 14.5
MO $117B PER 14.7
FAQ
What kind of company is XXII?
XXII belongs to the Consumer Defensive sector and operates in the Tobacco industry.
What is the market cap of XXII?
The market cap of XXII is approximately $1M, ranking 5,876 within its sector.
What is the 52-week high and low for XXII?
XXII has recorded a 52-week high of $646.50 and a low of $1.80.
